The GPR107 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population in which the GPR107 gene has been disrupted in the human A-549 lung carcinoma epithelial cell line. This product comprises a mixed population of edited cells, each carrying heterogeneous genetic modifications at the target locus, providing a robust loss-of-function model for studying GPR107 function. The use of a polyclonal format allows for rapid generation of knockout cells without clonal selection, enabling researchers to assess the overall impact of gene disruption while avoiding potential clonal artifacts.
The host cell line, A-549, was originally established from the lung carcinoma tissue of a 58-year-old male patient. These adherent epithelial cells are a widely accepted model for lung adenocarcinoma and respiratory epithelium, exhibiting key features of alveolar type II pneumocytes. A-549 cells are extensively utilized in cancer biology, drug discovery, and toxicology studies due to their well-characterized genetic background, stable growth properties, and responsiveness to various stimuli. Their use here provides a physiologically relevant context for investigating GPR107 in lung-derived tissue.
GPR107 is an orphan G protein-coupled receptor (GPCR) whose endogenous ligand remains unknown. As a member of the GPCR superfamily, it is predicted to transduce extracellular signals through heterotrimeric G proteins, including Gs and Gq subtypes, leading to modulation of key second messengers such as cyclic AMP (cAMP) and calcium. Downstream effectors include adenylate cyclase, phospholipase C, protein kinase A (PKA), and protein kinase C (PKC), which collectively orchestrate cellular responses. Additionally, GPR107 may engage canonical GPCR regulatory proteins such as ??-arrestins and G protein-coupled receptor kinases (GRKs), potentially influencing receptor desensitization and intracellular trafficking. This signalling framework integrates with broader cellular pathways, including MAPK/ERK cascades, which are pivotal in controlling cell proliferation, differentiation, and survival.
In the A-549 lung carcinoma context, GPR107 knockout is expected to perturb these signalling networks, potentially altering cAMP and calcium dynamics and downstream transcriptional programs. Given the involvement of GPCR signalling in cancer hallmarks, loss of GPR107 may affect A-549 cell viability, migration, or response to external cues. Thus, this knockout model offers a relevant platform for dissecting orphan GPCR contributions to lung cancer cell biology and for evaluating the therapeutic potential of targeting this receptor in pulmonary malignancies.
These polyclonal knockout cells are suitable for functional assays including cAMP accumulation, calcium flux, cell viability, and migration measurements to assess GPR107-mediated signalling. RNA-seq and western blotting for targets like phosphorylated PKA substrates or PKC components further elucidate molecular mechanisms. Applications encompass orphan GPCR characterization, GPCR signalling studies, lung cancer research, and drug target validation. For further details, contact Ascent Research.
